Latest research into retatritide peptide highlight promising possibility for addressing excess body and non-insulin dependent disease. The molecule, a dual agonist of GLP-1 and GIP receptor, appears to offer improved body mass and glycemic control in contrast to existing treatments. Additional patient studies are required to fully assess its safety